

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: EISENBACK-SCHWARTZ et al

Application No.: 09/218,277

Filed: December 22, 1998

For: T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR USES

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

Sir:



Art Unit: 1644

Examiner: S. Turner

Washington, D.C.

Atty.'s Docket: EIS-SCHWARTZ=1A

Date: June 16, 2000

*WJ*  
RECEIVED  
JUN 19 2000  
TECH CENTER 1600/2900

RECEIVED  
JUN 20 2000  
TECH CENTER 1600/2900

Transmitted herewith is a [ ] Amendment [XX] Response to Notice to Comply with Sequence Listing Requirements and disk in the above-identified application.

- [ ] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted
- [ ] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- No additional fee is required.
- [ ] The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT	(Col. 2) MINUS	(Col. 3) HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	**	20	0
INDEP.	*	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL \$

SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
x 9	\$		x 18	\$
x 39	\$		x 78	\$
+ 130	\$		+ 260	\$
ADDITIONAL FEE TOTAL			TOTAL	

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- \*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- [ ] First - \$ 55.00
- [ ] Second - \$ 190.00
- [ ] Third - \$ 435.00
- [ ] Fourth - \$ 680.00

Month After Time Period Set

[ ] Less fees (\$ \_\_\_\_\_) already paid for \_\_\_\_ month(s) extension of time on \_\_\_\_\_.

Other Than Small Entity

Response Filed Within

- [ ] First - \$ 110.00
- [ ] Second - \$ 380.00
- [ ] Third - \$ 870.00
- [ ] Fourth - \$ 1360.00

Month After Time Period Set

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ \_\_\_\_\_.

[ ] Please charge my American Express Account, Form PTO-2038 attached, in the amount of \$ \_\_\_\_\_.

[ ] A check in the amount of \$ \_\_\_\_\_ is attached (check no. \_\_\_\_\_).

The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

*[Handwritten signature of Allen C. Yun]*  
By: Allen C. Yun  
Registration No. 37,971

RECEIVED

JUN 20 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

EISENBACK-SCHWARTZ et al.

Appln. No.: 09/218,277

Filed: December 22, 1998

For: T-CELLS, NERVOUS SYSTEM-  
SPECIFIC ANTIGENS AND  
THEIR USES



Art Unit: 1644

Examiner: S. Turner

Washington, D.C.

June 16, 2000

Atty.Docket:  
EIS-SCHWARTZ=1A

1/11  
1/17  
1/30/00

**RESPONSE TO NOTICE TO COMPLY WITH  
SEQUENCE LISTING REQUIREMENTS**

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply, dated May 26,  
2000, please amend the present application as follows:

IN THE SPECIFICATION

Page 10, line 25, after "SEQ ID NO:" insert --1--;  
line 28, after "SEQ ID NO:" insert --2--;  
line 32, after "SEQ ID" replace "NO:" with  
--NOs:3-8--.

Page 11, line 5, after "SEQ ID NO:" insert --9--;  
line 10, after "SEQ ID NO:" insert --10--;  
line 14, after "SEQ ID NO:" insert --11--;  
line 18, after "SEQ ID NO:" insert --12--;  
line 22, after "SEQ ID NO:" insert --13--;  
line 24, after "SEQ ID NO:" insert --14--.

Page 18, line 27, after "SEQ ID NO:" insert --12--;  
line 28, after "SEQ ID NO:" insert --13--;  
line 29, after "SEQ ID NO:" insert --14--.